Which of the following may occur as an adverse effect of Vecuronium?

Vecuronium is a neuromuscular blocker commonly used in anesthesia and intensive care settings to facilitate intubation and provide muscle relaxation during surgery. One of the primary mechanisms of vecuronium is its ability to inhibit neurotransmission at the neuromuscular junction, leading to muscle paralysis. This muscle paralysis, while useful in controlled medical settings, can lead to adverse effects, particularly respiratory depression.

Respiratory depression occurs because the muscles responsible for breathing, including the diaphragm and intercostal muscles, may become paralyzed when vecuronium is administered. As a result, patients may not be able to initiate or effectively continue breathing on their own, necessitating careful monitoring and, in most cases, mechanical ventilation. This effect illustrates the importance of monitoring respiratory function when administering neuromuscular blockers like vecuronium to ensure patient safety.

The other options provided do not align with the primary adverse effects associated with vecuronium. While reduced muscle tone may occur as a direct consequence of the drug's action, it is not typically described as an adverse effect—it is the intended result. Severe agitation and increased alertness are not related to vecuronium's pharmacological profile, as muscle paralysis generally prevents any voluntary movements, thus not promoting agitation or